J&J buys GSK hep. C compound, BI completes trial enrollment

Share this article:
GSK misses on late-stage CV drug
GSK misses on late-stage CV drug

GlaxoSmithKline sold its investigational hepatitis C NS5a replication complex inhibitor to Johnson & Johnson subsidiary Janssen. The J&J unit said in a statement it plans to use Phase II GSK2336805 in interferon-free combinations with its in-house drug simeprevir and its non-nucleoside polymerase inhibitor known as TMC647055. Simeprevir is expected to go before an FDA advisory panel later this month.

This mix-and-match drug approach is common to the space, and competitor Gilead's investigational nucleotide hep. C virus polymerase inhibitor is set to go before an FDA committee one day after J&J's contender gets a thumbs-up or down.

As Boehringer Ingelheim noted in a statement Tuesday, an interferon-free hep. C treatment is an innovation of need, because around 50% of patients cannot take the infusion drugs. This is in addition to patients who are turned off by side effects and the amount of time it takes to complete a course of interferon therapy.

Boehringer's patient-perception walk-through was part of a larger HCV announcement, which was that it had completed enrollment for its all-oral Phase IIa treatment that combines BI's protease inhibitor faldaprevir, its non-nucleoside NS5B polymerase inhibitor deleobuvir, and Presidio Pharmaceutical's pan-genotypic NS5A inhibitor, PPI-668 with and without ribavirin. BI and Presidio's collaboration dates to March, with each company holding on to the rights of their respective compounds. A Phase IIIb faldaprevir-deleobuvir study showed strong efficacy among hepatitis C genotype 1 patients without interferon. Genotype-1 is the most difficult hep. c variation to treat.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...